Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: JACC Cardiovasc Interv. 2017 Nov 1;11(2):181–191. doi: 10.1016/j.jcin.2017.07.022

FIGURE 1. Study Population by CYP2C19 Genotype Group and Antiplatelet Therapy.

FIGURE 1

*Alternative therapy in patients with a LOF allele consisted of prasugrel (n=222), ticagrelor (n=116), or high dose clopidogrel (150 mg/day, n=2; 225 mg/day, n=6).

†Alternative therapy in the non-LOF group consisted of prasugrel (n=125) or ticagrelor (n=68).

‡p<0.001 for use of alternative therapy in the non-LOF group compared to the LOF group.

APT, antiplatelet therapy; LOF, loss-of-function; PCI, percutaneous coronary intervention